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Abstract
Background: Current tuberculosis regimens have failed to combat the issue of drug resistance and ethno
medicines may represent a possible source of antimycobacterial agents. Combretum species are well known in
African traditional medicines and used for various ailments including pneumonia, venereal diseases like syphilis,
mental problems, relief of sore throats and colds, fever, and chest coughs associated with tuberculosis. Alkaloids
function as either hydrogen-acceptor or hydrogen-donor in hydrogen bonding critical for the interaction between
targets thus, potentiating effects of curative agents on diseases. Alkaloid extracts from leaves of Combretum zeyheri,
Combretum platypetalum, Combretum molle and Combretum apiculatum, were assessed for antimycobacterial
activity to establish rationale for their use in traditional medicines for various ailments including pneumonia,
relief of sore throats and colds, fever, and chest coughs associated with tuberculosis.
Methods: Alkaloids were extracted from the leaves of Combretum zeyheri, Combretum platypetalum, Combretum
molle and Combretum apiculatum. The broth microdilution method was used for the screening of growth inhibitory
activity. The standard drug rifampicin was used as the positive control. Alkaloid extracts from the most potent
plant species, Combretum zeyheri were further investigated for time-kill dependency effects on drug transport in
Mycobacterium smegmatis.
Results: Using the broth microdilution susceptibility method, C. zeyheri alkaloid extract, was found to have the
most antimycobacterial effects with an MIC value of 125 μg/ml whilst MICs for C. molle and C. platypetalum were
above 1000 μg/ml. An MBC value of 250 μg/ml was observed with alkaloid extracts from Combretum zeyheri whilst
the remaining three Combretum species showed no bactericidal activity. It was also shown that C. zeyheri had
potential efflux pump inhibitory activity. Determination of the time-kill kinetics of extracts from C. zeyheri showed
not only a concentration-dependent activity but time-dependent bactericidal effect as well.
Conclusions: Alkaloid extracts from the leaves of C. zeyheri have potential as a source of lead compounds that may
be developed further into antimycobacterial compounds. The mechanism of action of may be due to inhibition
of transport across the cell membrane. Further work needs to be done to isolate the active components in these
extracts.
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Background
Tuberculosis (TB) is a bacterial infection caused by a bac-
terium called Mycobacterium tuberculosis. Unique about
mycobacterium, is the cell wall structure which contains
mycolic acids intercalated to peptidoglycan – associated
polysaccharides [1]. There are various strains of mycobac-
terium and transmission is through the lymph nodes and
the blood stream to any organ of the body but mainly af-
fects the lungs causing pulmonary tuberculosis. It may
disseminate to other body parts causing extra-pulmonary
tuberculosis [2]. The bacterium generally exists in its in-
active form and only a few people infected will develop
the active form of the disease [3]. Approximately 8 million
TB cases emerge every year whilst at most 5000 people
die from the disease everyday worldwide [4].
In most developing countries there is a relationship be-
tween HIV/AIDS and tuberculosis. According to the
World Health Organisation (WHO) one-third of patients
living with HIV are infected with TB [5]. Patients living
with HIV are 35 times more likely to become infected with
TB than people without HIV [6]. The treatment regimens
consist of a combination of 5 first line medicines; rifampi-
cin, isoniazid, pyrazinamide, ethambutol and streptomycin
(HREZS) [7]. The initial intensive phase of includes rifam-
picin, isoniazid, pyrazinamide and, ethambutol daily for
2 months and a continuation phase of rifampicin and iso-
niazid for a further 4 months, either daily or 3 times a
week [8]. Resistance of mycobacterium to conventional
drugs is mainly due to inadequate exposure of the TB
causing organism to anti-tuberculosis drugs [9]. The abil-
ity of mycobacterium strains to increase activity of their
efflux pumps preventing drugs from reaching intended
targets is amongst the major reasons of multi-drug resist-
ant tuberculosis (MDR-TB) [10]. Multi-drug resistance TB
occurs when mycobacterium do not respond to at least
isoniazid and rifampicin, which are part of the 2 first line
or standard anti-TB drugs. Extensive-drug resistance oc-
curs when mycobacterium becomes resistant to most of
the available drugs including most second line anti-TB
drugs [5].
There is a global increase in the use of herbal medi-
cines and developing countries tend to depend on these
plants more than other populations primarily because
of the limitations in modern healthcare facilities in
addition to cultural preferences [11]. To date, phytomedi-
cines have shown great potential in treating intractable in-
fectious diseases for example TB [4]. Approximately 80%
of the population in developing countries depend on trad-
itional medicines for their primary health care needs [12].
In acknowledgement of this fact, the WHO declared a
resolution on promoting the role of traditional medicine
in health systems, a strategy for the African region. For
most plants safety and efficacy profiles have not yet been
identified and this has posed a major challenge in trying
to merge traditional medicines and modern medicines in
order to improve the health care system. There is a need,
therefore, to evaluate and justify their respective pharma-
cological activities.
The family Combretaceae consists of approximately 20
genera and 600 species. This plant occurs mainly in
tropical and subtropical areas, like Africa and Brazil
[13]. The Combretaceae family of plants has been widely
used as traditional medicines [14]. Use of these plants to
treat scorpion and snake bites, and mental problems and
their use for the relief of sore throats and colds, fever,
chest coughs associated with tuberculosis, pneumonia
and venereal diseases like syphilis is common in most
African communities [15]. Studies on the genus have
shown presence of several phytochemical constituents
including alkaloids, saponins, tannins and cardiac glyco-
sides [16, 17]. To date there are over 27 000 alkaloid-
based compounds in the Dictionary of Natural Products
(DNPs) [18]. Alkaloid molecules can act, depending on a
type of amine functionality present in alkaloids, as either
hydrogen- acceptor or hydrogen-donor for hydrogen
bonding. This bonding is critically important for the inter-
action (binding) between targets, which may be enzymes,
proteins and receptors for drugs, thereby, potentiating the
drug effects in a pathology condition [19].
There is need for in vitro-screening of phytomedicines
so that there is validation of their traditional use and for
providing leads in the discovery of new active chemical
principles [3, 20]. The highly infectious nature of Myco-
bacterium tuberculosis restricts its use for large scale
screening of probable drug candidates [21]. Mycobacter-
ium smegmatis is a fast growing and non-pathogenic
strain compared to the disease-causing strain M. tuber-
culosis. M. smegmatis has been found to display a similar
drug sensitivity profile similar to M. tuberculosis [21]
and, therefore, this organism can be used as a primary
screen to shortlist compounds with antimycobacterial
activity. The objectives of this study, therefore, was to
evaluate the effects of alkaloid extracts from selected




The following chemicals and equipment were used and
these are: Phillips two-speed electric blender, 10% Etha-
nolic acetic acid, ammonia solution, Middlebrook 7H9
media, casein hydrosylate, agar, an incubator, dimethyl
sulphoxide (DMSO), dichloromethane (DCM), rifampi-
cin, ciprofloxacin, 96-well microtitre plates, a Biokinetics
Reader EL350, biosafety hazard safety cabinet level 2. All
the chemicals used were obtained from Sigma Aldrich
(Darmstadt, Germany)
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Plant collection and preparation of extracts
Combretum zeyheri and Combretum platypetalum
leaves were collected in Norton, Zimbabwe, geograph-
ical location 17.8833 ° S, 30.7000 ° E, 1364 m above sea-
level. Combretum molle and Combretum apiculatum
leaves were collected in Centenary (16.8°S, 31.1167°E, and
1156 m above sea level), Mashonaland Central Province,
Zimbabwe in the summer period (January-February,
2013). The plants identity was authenticated and classified
by Mr. Christopher Chapano, a taxonomist at the National
Herbarium and Botanic Gardens (Harare, Zimbabwe).
The samples were allocated a voucher specimen number
N6E7, N9E7, C1E7 and C2E7 for C. zeyheri, C. platypeta-
lum, C. apiculatum and C. molle respectively and herbar-
ium samples were kept at the National Botanic and
Herbarium Garden and the Department of Biochemistry,
University of Zimbabwe. The dried plant leaves were
ground using a two speed blender (Cole Parmer instru-
ments company, Vernon Hills, USA). Alkaloid phytocon-
stituents were extracted from the plants using a polar
solvent, 20 ml of 10% ethanolic acetic acid after which the
mixtures were left to stand for 4 h at room temperature a
method described by Harbone [22] with modifications.
Mixtures were filtered through a Whatman filter paper.
The filtrate was concentrated by evaporation over a steam
bath to a quarter of its original volume. To precipitate the
alkaloid, concentrated ammonia solution was added in
drops to the extract until it is in excess. Alkaloid precipi-
tates were recovered by filtration using previously weighed
filter paper after which 9% ammonia solution was added
to wash the precipitates. The precipitates were dried in an
oven at 60 °C for 30 min and reweighed [23].
Growth of mycobacteria
Mycobacterium smegmatis, Mc2155 was obtained from
Professor Daniel Steenkamp of the Department of Clinical
Laboratory Studies, University of Cape Town, South
Africa. A volume of 100 ml of liquid broth consisting of
0.52 g Middlebrook 7H9 media supplemented with 0.1 g
casein hydrosylate was prepared using boiled distilled
water, sterilised by autoclaving and used for the growth of
mycobacterium at 37 °C under aerobic conditions.
Determination of antimycobacterial activity
The alkaloid extracts from the plants were used to deter-
mine the minimal inhibition concentration (MIC) and the
minimal bactericidal concentration (MBC) using the broth
microdilution assay described by Martini and Eloff [24].
Extracts were initially dissolved in DMSO and, therefore,
the effects of DMSO were also investigated on M. smeg-
matis. The alkaloid extracts were serially diluted with
media from 1000 μg/ml up to 0.2 μg/ml using the broth.
Aliquots of 100 μl were placed into 96-well microtitre
plates in duplicate. Rifampicin was used as the positive
control. The plates were sealed with parafilm™ paper
and incubated in a container containing wet paper
towel over night at 37 °C in an incubating shaker (Jeio
Tech, Korea). Optical densities of the wells were read
using a microplate reader (Tecan Genios-Pro micro-
plate reader, GrÖdig, Austria) at 590 nm. A solution of
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT) was added and the plates were incu-
bated for 2 h. After the incubation, 25 μL of DMSO
was added to dissolve the purple formazan that would
have been formed. The wells that did not show any
colour change after MTT was added, indicated the con-
centration of the plant alkaloid extract that was able to
inhibit mycobacterium growth whereas a purple colour
change indicated mycobacterium growth [25]. MBCs of
the alkaloids were determined on Middlebrook media
7H9 agar.
Determination of drug efflux
Accumulation and efflux of the fluoroquinolone, cipro-
floxacin was performed in order to determine the effect
of plant alkaloid extract on mycobacterium efflux pumps
as described by Mortimer and Piddock [26] with some
modifications. Mycobacterium were grown in Middleb-
rook 7H9 supplemented with casein hydrosylate media
in 3 separate flasks containing 400 mls media and grown
over 2 days at 37 °C. The mycobacteria were harvested
by centrifugation at 3000 rpm in a Hettich Rotofix 32
centrifuge (Tuttlingen, Germany) for 10 min in pre-
weighed tubes and the supernatant discarded. Bacteria
were then washed twice with 50 mM sodium phosphate
buffer (PBS) (pH 7.2). The cells were weighed and a vol-
ume needed to make up a volume of 40 mg/ml was
made in 10 mM PBS containing sodium azide. The mix-
ture was incubated at 37 °C for 15 min. Ciprofloxacin
was added to the mixture to a final concentration of
20 μg/ml. The mixture was incubated at 37 °C with
shaking at 120 rpm for 1 h (Lab Companion, Jeio Tech,
Seoul, South Korea). The sample was divided into two
aliquots a two-third and one-third volume sample which
was centrifuged at 3000 rpm for 5 min. The supernatant
was discarded and the pellet was weighed. PBS was
added to the one third sample to make up to a concen-
tration of 40 mg/ml, this tube representing a sample
without glucose. After discarding the supernatant and
weighing the pellet PBS containing 1 M glucose was
added to the two-third sample which was further sub-
divided into 3 equal aliquots of 40 mg/ml containing ei-
ther reserpine, DMSO, or the alkaloid plant extract from
Combretum zeyheri.
In order to rule out the effect of the solvent DMSO,
was also added in one of the tubes as it was the organic
solvent used to dissolve reserpine and the alkaloid ex-
tract. The samples were mixed by vortexing before being
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incubated for 30 min at 37 °C with shaking at 120 rpm.
After incubation, cells were washed with chilled phos-
phate buffer and re-centrifuged for 10 min at 4000 rpm.
After the supernatant was discarded, the pellet was re-
suspended in glycine hydrochloride 3.0 ml (0.1 M,
pH 3.0) with agitation to ensure exposure of the cells to
the lysis buffer. The samples were incubated at 37 C,
120 rpm for overnight. The samples were then centri-
fuged for 10 min at 3000 rpm to sediment cell debris.
The fluorescence of ciprofloxacin in the supernatant was
determined at the excitation and emission wavelengths
of 270 nm and 452 nm respectively using an RF – 1501
Shimadzu spectrofluorimeter (Shimadzu Cooperation,
Tokyo, Japan). Both supernatant samples from the intact
cells (representing efflux samples) and the lysed cells
(representing influx samples) were quantified for cipro-
floxacin using a standard curve. To rule out interference
from the reserpine and the plant extracts, their fluores-
cence was determined at the same excitation and emis-
sion wavelength as ciprofloxacin.
Time-kill assay
Time-kill assays were carried out with modifications
from Oladosu et al., [27]. M. smegmatis was grown over-
night at 37 °C in Middlebrook 7H9 media supplemented
with casein hydrolysate. The plant alkaloid extracts were
serially diluted with media from 1000 μg/ml up to
0.2 μg/ml to make ten 2-fold microdilutions for the
microbroth dilution assay. Aliquots of 100 μl were plated
onto 96-well microtitre plates in duplicate. Rifampicin
was used as the positive control at 2-fold increasing con-
centrations of from 0.1 μg/ml to 50 μg/ml. The extracts
and rifampicin were cultured with the inoculum at a
final concentration of 1 × 106 cfu/ml. In order to rule
out interference from the media the plant extract was in-
cubated with media only. The plates were sealed with
parafilm™ paper and incubated in a container containing
wet paper towel over night at 37C in an incubating
shaker (Jeio Tech, Korea). At defined time intervals (0,
2, 4, 6, 8, and 24 h), the size of the bacterial population
was quantified to characterise the effect of the different
extract concentrations. This was done by plating 10 μl
aliquots of each dilution (10 μl samples diluted up to
1 ml with media) and plated on 40 ml solid agar plates.
Only 250 μg/ml, 125 μg/ml, and 63 μg/ml extract con-
centrations were plated. Plates were incubated for 24 h
at 37 °C. The number of viable organisms were counted
as cfu/plate. Surviving organisms were determined by
the plate count method at sampling time and enumer-
ated. Average duplicate (2 plates from each replicate di-
lution) counts were multiplied by the dilution factor to
derive the concentration of cells as cfu/ml. The percent-
age reduction from initial microbial population for each
time point was calculated to express the change
(reduction or increase) of the microorganism population
relative to a starting inoculum. The change was deter-
mined as follows:
% Reduction ¼ initial count – count at x interval=
initial count
  100
The number of surviving microorganisms in the extract
was determined by plate-count method at sampling time
and enumerated. Optical densities signifying bacterial cell
density of the wells were also read using a Genios Pro
microplate reader (Tecan Instruments, Grodig, Austria) at
590 nm. The results were analysed using ANOVA with
graph pad ™ version 5 for Windows (Graph pad ™ Software
Inc. Scan Diego, California. USA).
Statistical analyses
Numerical data was analysed using graph pad ™ version 5
for Windows (Graph pad ™ Software Inc. Scan Diego,
California. USA). Statistical analysis was carried out using
One-way ANOVA where values of P < 0.05 are regarded
as significant (95% confidence interval). A post-hoc
analysis (Dunnet’s multiple comparison test) was used
Graphpad Prism (Version 5.0, Graph pad Software Inc,
San Diego, USA).
Results
Extraction of plant phytoconstituents and
antimycobacterial activity determination
Alkaloid extracts from 4 plant species namely: Combretum
apiculatum, Combretum molle, Combretum platypetalum
and Combretum zeyheri were tested for antimycobacterial
activity. Extraction was carried out using 10% acetic etha-
nolic acid, and percentage yields are shown in Table 1.
The effects of the solvent was determined and the results
are shown in Fig. 1. A DMSO solvent concentration of
2.5% was used for all the subsequent assays. In order to
quantify the activity of alkaloid extracts from the four
plant species, the broth microdilution method was used.
This allowed determination of the minimum inhibitory
concentration and subsequently the minimum bactericidal
concentration. Varying concentrations of the plant ex-
tracts were tested and these ranged from 1000 μg/ml to
2 μg/ml attained by 2-fold dilutions. Of the four plant
Table 1 The extractive values and percentage yields of crude
10% ethanolic acetic acid extracts
Name of plant species Amount extracted
per 50 g samplea
Percentage yield (%)
C. platypetalum 0.108 0.432
C. apiculatum 0.049 0.196
C. zeyheri 0.605 2.42
C. molle 0.371 1.484
The alkaloids were extracted according to the method by Harbone [23]
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species extracts tested, C. zeyheri alkaloid extract was the
most effective in inhibiting the growth of Mycobacterium
smegmatis. Rifampicin was used as the positive control
whilst the negative control was cells and media only
(Fig. 2). Figure 3 shows the effects of the C. zeyheri alka-
loids on the growth of mycobacteria. MICs of 1000 μg/ml,
>1000 μg/ml and 125 μg/ml were obtained for C. molle, C.
platypetalum and C. zeyheri respectively (Table 2). The
purple formazan colour that was quantified spectrophoto-
metrically indicated presence of viable cells showing
mycobacterium growth (Fig. 4). Wells that showed no
colour change after addition of MTT (yellow colour)
represented concentration of the plant extracts that were
able to inhibit mycobacterium growth (1000 – 125 μg/ml).
Combretum platypetalum alkaloid extracts also showed
that they had antimycobacterial effects but the these ef-
fects were lower than those of C. zeyheri (Fig. 5)
Time–kill kinetics of alkaloid extracts from C. zeyheri on
Mycobacterium smegmatis
Alkaloid extracts from Combretum zeyheri showed
concentration-dependent killing with a minimum in-
hibitory concentration of 125 μg/ml and a minimum
bactericidal concentration of 250 μg/ml using the broth
microdilution method (Fig. 6). Concentrations from 0-
1000 μg/ml were used. In order to also determine kill-
ing capacity of the extract; a time-kill assay was carried
out. For the time-dependent assay, a range of three
concentration 63 μg/ml, 125 μg/ml and 250 μg/ml were
used. The antimycobactericidal capacity of the alkaloid
extract from C. zeyheri was highly time-dependent. At the
highest concentration of 250 μg/ml 100% bactericidal
activity was achieved after a time period of 8 h. No
growth was observed after 24 h. At 250 μg/ml the bac-
tericidal activity of the extract was quite efficient and
time-dependent with a decrease in the number of col-
ony forming units per ml (cfu/ml) over time intervals 0,
2, 4, 6, 8 and 24 h respectively. At a concentration of
125 μg/ml a decrease in the number of cfu/ml was ob-
served. The antimycobactericidal capacity was moderate
with ≥ 90% killing achieved after 8 h calculated as the per-
centage reduction [27]. For both the 125 and 250 μg/ml,
there was a decrease in the colony forming units which
was time-dependent. In terms of efficiency of killing, the
graph shows that the 250 μg/ml was more effective than
125 μg/ml at 0 and 4 h post incubation. However, in both
cases of the concentrations, 100% killing activity was not
achieved although concentration-dependent killing was
achieved (Fig. 6). At 63 μg/ml, similar growth with the
control was obtained. After 24 hM. smegmatis suspension
in the 63 μg/ml sample was aggregated as characterised by
the cloudy appearance of cells and this was probably
due to increased mycobacterium cell density. Alkaloid
extracts of C. zeyheri showed concentration-dependent
killing with a decrease in the number of surviving col-
onies being observed from the lowest to the highest
concentrations. A significant decrease in population of
test organisms was observed at each interval with the
percentage reduction in viable cell count observed to
be from 40% to 90% and 13.3% to 100% between 2 to
24 h of interaction at the 125 μg/ml concentration and
at 250 μg/ml concentration respectively. This repre-
sented a significant decrease in microbial population
particularly at 250 μg/ml.
Effect of plant extracts on Mycobacterium smegmatis
efflux pumps
Of the 4 Combretaceae plant species tested; alkaloid ex-
tracts from Combretum zeyheri were the most effective
in inhibiting drug efflux. The effect of extracts from C.
zeyheri on efflux pumps in M. smegmatis was deter-
mined using the ciprofloxacin accumulation assay. Ac-
tive accumulation of ciprofloxacin in M. smegmatis was
monitored in the presence and absence of plant extracts
and for comparison accumulation of ciprofloxacin was
monitored in the presence of reserpine, a known efflux
pump inhibitor. The ability of the plant alkaloid extracts
in inhibiting efflux pump activity in M. smegmatis was
comparable to that of reserpine a known efflux pump
inhibitor. As shown in Fig. 7, there was no significant
difference between the sample containing reserpine and
glucose versus the sample containing the extract from C.
zeyheri and glucose indicating that reserpine inhibited
drug efflux. Similarly the alkaloid extract inhibited the
efflux of ciprofloxacin from the cells to the same extent
as reserpine.

Fig. 1 The effect of different concentrations of DMSO on M.
smegmatis. Mycobacterium smegmatis was grown in broth and
exposed to varying concentrations of DMSO in 96-well microplates.
*** P < 0.001 in comparison with the 0% DMSO. Values are the
mean ± SD for N = 6
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Discussion
Due to the emergence of multi-drug resistant mycobac-
terium, new alternatives for the treatment of tubercu-
losis are urgently needed. Statistics show that every year,
8 million people are infected with TB whilst 2 million
deaths are reported annually [28]. When a patient be-
comes resistant to anti-tuberculosis drugs, particularly
isoniazid and rifampicin, they have a 40% chance of sur-
vival regardless of their HIV status [6]. In addition, TB
treatment protocols are long in duration causing pa-
tients to default from taking their medication and there
is no sufficient treatment for multi-drug resistant TB
(MDR-TB) [29]. At least 24 species of Combretum are
well known in African traditional medicine and are used

Fig. 2 The effects of rifampicin (positive control) on the growth of mycobacterium in broth. M. smegmatis were grown and exposed to increasing
concentrations of rifampicin in a 96-well microplate. Values are the mean of ± SD for n = 4 for duplicate measurements *P < 0.05 ** P < 0.01,
*** P < 0.001 in comparison with the cells exposed to the zero concentration of extract
Fig. 3 The growth inhibitory properties of alkaloid extracts from C. zeyheri on Mycobacterium smegmatis. The broth microdilution method was
used to determine growth inhibitory properties of extracts using a 96-well microtitre plate. A minimum inhibitory concentration of 125 μg/ml
was observed and the optical densities of the wells were read using a microplate reader (Tecan Genios-Pro microplate reader, GrÖdig, Austria)
at 590 nm. Values are the mean of ± SD for n = 4.*** P < 0.001 in comparison with the cells exposed to the zero concentration of extract
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for the treatment of a variety of ailments and diseases,
ranging from scorpion stings and snake bites, mental
problems, heart and worm remedies and microbial infec-
tions [30]. The therapeutic effects of these medicinal
plants is due to the presence of particular substances in
plants most of which are phenols or their derivatives.
These phytochemicals may not have direct physiological
activity within the plant itself but have significant bio-
logical effects on animals [4].
Differences in yields for the four Combretum species
were observed on extraction of the alkaloid phytoconsti-
tuents. This is not unusual as variations in biological
activity and quantity of the phytochemicals present in
the plant extract occur due to various reasons that
include: plant age, differences in geographical areas in
harvest sites and also seasonal variations [31].
When patients are inadequately exposed to anti-
tuberculosis drugs, this may result in the emergence of
resistant mycobacterium [31]. Drug resistance may be
classified as phenotypic or genotypic resistance. Pheno-
typic drug resistance occurs when mycobacterium are
only slightly affected by the anti-tuberculosis drugs
such as rifampicin. This type of resistance maybe due
to porin loss, increased efflux pump activity or presence
of drug–modifying enzymes which will reduce desired
drug concentrations intracellularly. Genotypic drug
resistance is usually linked to mutations in mycobacterium
genome and most of these mutations are known [9].
The uses of traditional medicines as alternative forms of
health care provision are accepted, particularly in develop-
ing countries [32]. This led us to the investigation of the
effects of alkaloid extracts from four Combretaceae family
plant species on anti-mycobacterium activity. The need to
use plant species belonging to the Combretaceae family of
plants and investigating their effects on M. smegmatis was
based on the ethnomedicinal use of these plants in
Zimbabwe [33, 34] and other African countries in this re-
gion where the plants are used in the treatment of symp-
toms associated with TB such as persistent cough, chest
pains and fever [8].
Using the broth microdilution method it was shown that
alkaloid extract from Combretum zeyheri was the most
potent against the mycobacterium with a minimum in-
hibitory concentration of 125 μg/ml and a minimum
bactericidal concentration of 250 μg/ml. Extracts from C.
molle and C. platypetalum were inactive with MICs above
1000 μg/ml whilst extracts from C. apiculatum were in-
conclusive. The criteria for an active plant extract has
been given as MIC values of 128 μg/ml or IC50 values of
less than 100 μg/ml [35]. Activity with plant extracts is
considered to be moderate when 100 <MIC < 625 μg/ml
[28]. In this regard, the alkaloid extract of C. zeyheri can
be considered to have significant antimycobacterial effects.
An MIC above 1000 μg/ml for crude extracts is cate-
gorised as being inactive against mycobacterium. This is
because these are crude extracts of the plants and so MICs
will not be a reliable indicator of the isolation of a potent
antimycobacterial compound, thus, the lower the MIC,
the more significant the result [36]. The front-line anti-TB
drugs, such as rifampicin have MICs in the range of 0.025
– 0.20 μg/ml and if compared to the activity of any new
extracts, a new compound must have an activity in the
Table 2 The effects of the alkaloid –enriched leaf extracts against
Mycobacterium smegmatis at 1000 μg/ml
Combretum species Activity at 1000 μg/mla MIC (μg/ml)b
C. platypelatum Moderately Active >1000
C. apiculutum Inactive >1000
C. molle Moderately active 1000
C. zeyheri Active 125
aActivity at 1000 μg/ml, bMinimum inhibitory concentration
Fig. 4 MTT assay showing the growth inhibitory effects of alkaloid extracts from C. zeyheri on M. smegmatis. Viable cells are coloured purple whilst
metabolically inactive cells are coloured yellow. The intensity of the purple also shows levels of cell activity
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same range. However, these are crude extracts on which
no further purification process has been carried out,
hence, they may be considered active at higher concentra-
tions as well particularly for C. zeyheri.
A time-kill assay aims to determine not only
concentration-dependent killing capacity of drugs or
plant extracts, but also the time – dependent killing ac-
tivity of these agents. A wide range of concentrations of
the drug or extract are used and mycobacterial killing
at different time points is determined. This is done dur-
ing exposure of the mycobacterium to the drug or plant
extract being used. Therefore, instead of only obtaining
results at the end – point; more detailed information is
provided as to the different killing capacities of these
agents at fluctuating concentrations [9]. This study, un-
like a MIC/MBC assay, allows the determination of the
speed of bactericidal activity of the extract [27].
An ideal anti-TB should show a high killing rate with a
concomitant decrease in mycobacterial load reducing
the risk of developing resistance or spreading the dis-
ease. The results of the present study provide insight
into the in vitro killing dynamics of plant species belong-
ing to the Combretaceae family of plants with respect to
the killing capacity (concentration-dependence) and the
Fig. 5 The effects of C. platypetalum alkaloid extracts on mycobacterium in broth. M. smegmatis were grown in broth and exposed to increasing
concentrations of C. platypetalum leaf alkaloid extracts in a 96-well microplate. Values are the mean of ± SD for n = 4. *P < 0.05; ** P < 0.01 in
comparison with the cells exposed to the zero concentration of extract
Fig. 6 Time dependent and concentration – dependent bactericidal effect of alkaloid extracts from C. zeyheri on M. smegmatis. Cultures of M.
smegmatis standardised to 1 x 106 cfu/ml were exposed to alkaloid extracts from C. zeyheri at 2-fold increasing concentrations from 2 μg/ml to
1000 μg/ml over 24 h at 37̊ C. After 2, 4, 6, 8 and 24 h of exposure samples were taken to determine number of surviving populations at 0, 63,
125, and 250 μg/ml
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rate of killing (time-dependence). Of interest is the adap-
tation or acclimatisation phase of microorganisms which
was observed between the 2 h and 4 h interval at
125 μg/ml. This phase is characterised by some form of
growth though minimal as microorganisms are acclima-
tising to the environment. However, because microbial
cells were in a toxic environment, cell death occurred
soon after and this was quite rapid at 250 μg/ml. A
sharp decrease in microbial population was to be ex-
pected at higher concentrations (500 – 1000 μg/ml).
However, the nature of the assay required concentration
values close to those of the MIC of the most potent
plant species.
Resistance of mycobacterium to anti-TB agents is
hinged on a number of factors which include presence of
efflux pumps which the major factor is contributing to in-
trinsic resistance [37]. Also, the nature of the mycobacter-
ium cell wall makes it extremely impermeable to a wide
range of agents due to its complex system of mycolic acids
intercalated to a whole range of lipids and polymers [38].
Glucose transport systems in M. smegmatis belong to
a family of transporters called the ATP-binding cassette
(ABC) transporter family. Mycobacterium tuberculosis
possesses five sugar import systems. However, Myco-
bacterium smegmatis has 28 such transporters which
it also uses to pump out foreign compounds [39]. M.
smegmatis is the microbial species of choice to use in
learning more about mycobacterium physiology in
vitro [21]. Furthermore, M. smegmatis is non-
pathogenic in nature and is also fast growing [40].
Ciprofloxacin is a potent antimycobacterial agent (sec-
ond line) that targets genetic material specifically
DNA gyrase and topoisomerase IV. In order to study
the transport of agents across cell membranes a detec-
tion compound must be utilized. Detection com-
pounds vary and include use of radioactive isotopes of
common efflux pump substrates [37]. In this study,
ciprofloxacin was used to quantify the accumulated
amount inside the cell, thereby, assessing the effects of
plant extracts on the drug pumping activity of ATP-
binding cassette proteins in M. smegmatis.
Plant alkaloid extracts from C. zeyheri were the most
potent of the four plant extracts in inhibiting the trans-
port of ciproflocaxin. Reserpine is a plant alkaloid-based
drug which was used clinically as an antihypertensive
agent and as an anti-psychotic agent as well, although
Fig. 7 Effects of alkaloid extracts from C. zeyheri on drug accumulation in mycobacteria. Cells were loaded with ciprofloxacin and incubated for
an hour. Cells were centrifuged, supernatant removed and exposed to the various compounds in buffer with glucose. One sample was exposed
to the buffer alone with no glucose being added and this was the control. Cells were then centrifuged again and lysed with glycine-HCl. Cell
debris was collected by centrifugation and the amount of ciprofloxacin in the supernatant quantified at excitation and emission wavelengths of
270 nm and 452 nm respectively using an RF1501 Shimadzu spectrofluorimeter. Values are the mean of ± SD for n = 2 for duplicate determinations
**P < 0.01 in comparison with the cells exposed to glucose only
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rarely used nowadays clinically due to toxic adverse
effects [41]. It is a known efflux pump inhibitor. Re-
duced levels of ciprofloxacin were pumped out of the
mycobacterial cells compared to the cells incubated
with glucose and hence, more of the drug accumulated
within the cell. Though comparable with the activity
observed with reserpine, the extract did not result in
greater accumulation of the drug inside the cells. Con-
sidering the moderate MIC of extracts from C. zeyheri
(125 μg/ml), and comparable efflux pump inhibition to
a known inhibitor, reserpine, the results suggest that
besides possessing antimycobacterial activity, inhibition
of efflux pumps could be a mechanism of action of
these extracts [42].
There are many mechanisms by which phytochemicals
may act on Mycobacteria and these include inhibition of
cell wall synthesis, protein synthesis, interference with
membrane integrity and others [43]. The aim of this
study was first determine if an alkaloid extract had an ef-
fect on the growth of M. smegmatis. Since Mycobacteria
are known to be inherently resistant to antimycobacter-
ial agents because of the complex cell wall, and also be-
cause they pump out xenobiotics including anti-TB
drugs, we tested if the antimycobacterial action of the al-
kaloid extracts could be due to interference with drug
efflux. Our results show that the alkaloid extract pre-
vented the efflux of ciprofloxacin from M. smegmatis.
These findings would assist in the isolation of alkaloid
compounds that have efflux inhibitory activity in Myco-
bacteria from this plant. There are reports of increased
efflux pump expression in Mycobacterium tuberculosis
in clinical isolates and efflux pump inhibitors such as
verapamil have been used to enhance the antimycobac-
terial effects [44, 45]. Thus, inhibition of efflux pumps
should be manipulated as a target for new antimicrobial
agents in drug development. Furthermore, if such prom-
ising antimicrobial effects are possessed with crude
extracts that have not undergone an isolation and purifi-
cation process then the extraction of the active com-
pound responsible for these effects might result in
greater inhibitory activity.
Conclusions
The alkaloid extracts from the plant species, C. zeyheri,
were the most potent and displayed potent antimycobac-
terial activity towards M. smegmatis. In addition not
only was there concentration-dependent killing capacity
observed but also, time time-dependent killing activity
as well. The extracts showed potential efflux-pump in-
hibitory activity, hence, further studies of this plant may
lead to isolation of the bioactive compound. It is, there-
fore, essential to carry out isolation, purification and
antimycobacterial evaluation of phytochemicals from
Combretum zeyheri.
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